Candidate: Vaccine to protect against COVID-19

Category: VAX

Type: Fully-deleted, helper virus-independent adenovirus-based vector vaccine based on the company’s GreVac™ Plug-And-Play Technology

Status: Greffex on March 11 said it was prepared to advance its vaccine candidate into animal testing, with a commitment to distributing its vaccine for free to other countries upon approval. Two days earlier, Greffex CEO John Price told Fox News Channel’s “America’s Newsroom” broadcast that his company aimed to get its vaccine approved and available to patients by year’s end.

Last year, Greffex was awarded an $18.9 million contract from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), toward developing its GreVac™ Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases.

Greffex says it has developed the world’s first universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy, and safety by using proprietary clean viral vectors. The company has a pipeline of 12 vaccines that includes candidates for influenza, MERS-CoV, anthrax, Ebola, tetravalent Dengue, and Zika.

COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:


Previous articleVaxart, Emergent BioSolutions, and Kindred Biosciences – VXA-CoV2-1
Next articleKleo Pharmaceuticals and Green Cross LabCell (GCLC)–65